- Home
- A-Z Publications
- Current Cancer Drug Targets
- Fast Track Listing
Current Cancer Drug Targets - Online First
Description text for Online First listing goes here...
30
results
21 - 30 of 30 results
-
-
Identification of PANoptosis Subtypes to Assess the Prognosis and Immune Microenvironment of Lung Adenocarcinoma Patients: A Bioinformatics Combined Machine Learning Study
Authors: Xiaofeng Zhou, Bolin Wang, Di Wu, Lu Gao, Zhihua Wan and Ruifeng WuAvailable online: 14 October 2024More LessBackground PANoptosis, a novelty mechanism of cell death involving crosstalk between apoptosis, pyroptosis, and necroptosis, is strongly associated with tumor cell death and immunotherapy efficacy. However, its relevance in lung adenocarcinoma (LUAD) remains to be elucidated. Methods In this study, we acquired 18 PANoptosis-related differentially expressed gene (PRDEG) of LUAD. Based on these genes, LUAD s Read More
-
-
-
A Combination Therapy of Cyclophosphamide and Immunomodulating Agents in Cancer
Authors: Siti Nursyahirah Bakar and Chin Siang KueAvailable online: 08 October 2024More LessCyclophosphamide is a precursor of alkylating nitrogen mustard and was initially claimed to have antineoplastic and immunosuppressive properties. However, the role of cyclophosphamide as an immune activator has also been reported, depending on the dosage used. The application of lower-dose cyclophosphamide has emerged as a potential approach to cancer treatment. Cyclophosphamide selectively depletes regulatory T Read More
-
-
-
Role of Immunotherapy in the Management of Advanced Hepatocellular Carcinoma: A Systematic Review
Available online: 07 October 2024More LessIntroduction:The most prevalent histologic subtype of primary liver cancer, hepatocellular carcinoma, is also the third most lethal malignancy worldwide and a significant cause of cancer death. When diagnosed, it is frequently too late for curative therapies. To add to the difficulty, it is resistant to conventional systemic therapies like chemotherapy. Methods: Recently, more attention has been given to the use of immuno Read More
-
-
-
A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance
Authors: Jing Wu, Pan Deng, La Zou, Xiaoyu Liu, Xianjun Tang, Xiaohua Zeng and Shengchun LiuAvailable online: 01 October 2024More LessBackground Apatinib, a tyrosine-kinase inhibitor that targets the vascular endothelial growth factor receptor 2, contributes to the inhibition of angiogenesis. Vinorelbine, a semisynthetic vinca alkaloid, primarily inhibits metaphase mitosis of cancer cells through its interactions with tubulin. This study aimed to evaluate whether apatinib combined with vinorelbine was effective and safe for refractory human epidermal growth Read More
-
-
-
MMP7, Regulated by c-Jun, is Involved in Oral Squamous Cell Carcinoma and Associated with Cancer-Related Fibroblasts Infiltration
Authors: Jian Wei, Xiaoxi Jiang, Yiwen Xu, Minhai Nie, Sen Yang, Xiao Chen, Lijuan Huang and Xuqian LiuAvailable online: 01 October 2024More LessObjective This study aimed to analyze the expression of Matrix Metalloproteinase 7 (MMP7) and molecular mechanism at the Transcription Factor (TF) level in Oral Squamous Cell Carcinoma (OSCC). Methods MMP7 expression was preliminarily explored in Head and Neck Squamous Cell Carcinoma (HNSCC) in the online database, followed by functional analysis and prediction of TF of MMP7. IHC was employed to detect M Read More
-
-
-
Expression, Characteristics, and Clinical Target Prediction of PIK3C3/ vps34 in Gastric Cancer
Authors: Chenglou Zhu, Wenhan Liu and Mingxu DaAvailable online: 01 October 2024More LessObjective This study aimed to investigate the expression pattern of phosphatidylinositol 3-kinase class III (PIK3C3/vps34) in gastric cancer (GC) tissues and their juxtaposed normal counterparts and its correlation with the clinicopathological attributes and prognostic outlook of afflicted individuals. Methods Immunohistochemical (IHC) staining was used to ascertain the expression levels of PIK3C3/vps34 across 60 GC tissu Read More
-
-
-
The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer
Available online: 30 September 2024More LessImmunotherapy, as a novel treatment approach for various disorders, including cancers, is designed to either stimulate or suppress the immune system with high specificity. The recent achievements of this therapy in clinical trials are set to transform traditional treatment methods. Furthermore, it holds promise for enhancing the survival rates of patients suffering from both metastatic cancers and primary stages. G Read More
-
-
-
Disulfiram-Copper Potentiates Anticancer Efficacy of Standard Chemotherapy Drugs in Bladder Cancer Animal Model through ROS-Autophagy-Ferroptosis Signalling Cascade
Available online: 25 September 2024More LessBackground Cost-effective management of Urinary Bladder Cancer (UBC) is an unmet need. Aims Our study aims to demonstrate the efficacy of a drug repurposing strategy by using disulfiram (DSF) and copper gluconate (Cu) as an add-on treatment combination to traditional GC-based chemotherapy against N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced UBC mice (C57J) model. Methods Male C57BL/6J mice wer Read More
-
-
-
Regulation and Crosstalk of Cells and Factors in the Pancreatic Cancer Microenvironment
Authors: Jia Xu, Songmei Lou, Hui Huang, Jian Xu and Feng LuoAvailable online: 02 September 2024More LessPancreatic cancer is a highly malignant form of cancer that distinguishes itself from other gastrointestinal tumors through significant fibrosis and unique perineural invasion. These characteristics underscore the complexity of neural regulation within the pancreatic cancer Tumor Microenvironment (TME). This review aimed to explore the regulatory mechanisms and crosstalk among stromal cells and their factors Read More
-
-
-
The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets
Authors: Muhsen Al-Diabat, Nehad M. Ayoub, Laith AL Eitan, Moath Alshorman and Aymen ShatnawiAvailable online: 24 June 2024More LessIntroduction The heterogeneity of breast cancer requires exploring novel prognostic biomarkers as well as therapeutic targets for the treatment of the disease. Methods The METABRIC dataset was used to describe the gene expression of the programmed death-ligand 1 (PD-L1) and the hepatocyte growth factor receptor (MET) and their association with the tumor clinicopathologic characteristics and overall survival in br Read More
-